Johnson & Johnson MedTech (NYSE: JNJ) announced that it received CE mark approval for its dual-energy ThermoCool SmartTouch ...
Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced European CE mark approval of the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter for the treatment of cardiac ...
Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...
The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.
Johnson & Johnson’s JNJ MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to ...
Deutsche Bank upgraded Boston Scientific (BSX) to Buy from Hold with a price target of $108, up from $87. Boston Scientific’s :story has become simpler” following Johnson & Johnson’s (JNJ) ...
The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.
The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...
Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of ...